Authors: Zhao J, Yang Y, Huang H, Li D, Gu D PMID: 32750119 PMCID: PMC7454371 DOI: 10.1093/cid/ciaa1150 Abstract To explore any relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility, we compared ABO blood group distributions in 2173 COVID-19 patients with local control populations, and found that blood group A was [...]

Authors: Tomassa-Irriguible TM, Lielsa-Berrocal L PMID: 34243781 PMCID: PMC8269403 DOI: 10.1186/s12937-021-00727-z Abstract There are limited proven therapeutic options for the prevention and treatment of COVID-19. We underwent an observational study with the aim of measure plasma vitamin C levels in a population of critically ill COVID-19 adult patients who met ARDS criteria according to the [...]

Authors: Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR PMID: 34264329 PMCID: PMC8283561 DOI: 10.1001/jamanetworkopen.2021.14741 Abstract Importance: Randomized clinical trials have yielded conflicting results about the effects of remdesivir therapy on survival and length of hospital stay among people with COVID-19. Objective: To examine associations between remdesivir treatment and survival and length of [...]

Authors: Al Sulaiman K, Aljuhani O, Al Dossari M, Alshahrani A, Alharbi A PMID: 34193235 PMCID: PMC8242279 DOI: 10.1186/s13054-021-03648-9 Abstract Background: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine [...]

Authors: Assimakopoulos SF, Aretha D, Kominos D, Dimitropoulou D, Lagadinou M PMID: 34182881 DOI: 10.1080/23744235.2021.1945675 Abstract Background: N-acetyl-cysteine (NAC) has been previously shown to exert beneficial effects in diverse respiratory diseases, through antioxidant and anti-inflammatory actions. Our aim was to evaluate NAC potential impact in hospitalised patients with COVID-19 pneumonia, in [...]

Authors: Patterson BK, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A PMID: 34262570 PMCID: PMC8273732 DOI: 10.3389/fimmu.2021.700782 Abstract Expression of CCR5 and its cognate ligands have been implicated in COVID-19 pathogenesis, consequently therapeutics directed against CCR5 are being investigated. Here, we explored the role of CCR5 and its ligands [...]

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

Authors: Blum VF, Cimerman S, Huneter JR, Tierno P, Lacerda A, Soeiro A PMID: 34222847 PMCID: PMC8235996 DOI: 10.1016/j.eclinm.2021.100981 Abstract Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates' drugs. Nitazoxanide (NTZ) has a broad antiviral effect. Methods: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 [...]

Authors: Colunga Biancatelli RM, Solopov P, Sharlow E, Lazo J, Marik PE, Catravas J PMID: 34156871 PMCID: PMC8384477 DOI: 10.1152/ajplung.00223.2021 Abstract Acute lung injury (ALI) leading to acute respiratory distress syndrome is the major cause of COVID-19 lethality. Cell entry of SARS-CoV-2 occurs via the interaction between its surface spike protein (SP) and angiotensin-converting enzyme-2 [...]

Authors: Cadegiani FA, McCoy J, Zimerman A, Mirza FN, Barros RN doi: https://doi.org/10.1101/2021.06.22.21259318 Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that treatment with proxalutamide, a non-steroidal androgen receptor antagonist, accelerates viral clearance and [...]